甘李药业(603087) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥980.24 million, a year-on-year increase of 5.39%[5] - Total profit for the period was ¥234.69 million, reflecting a growth of 5.36% compared to the same period last year[5] - Net profit attributable to shareholders was ¥214.66 million, up 3.02% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥204.51 million, showing a significant increase of 11.25%[5] - Basic earnings per share for the period were ¥0.36, representing a 2.86% increase compared to the previous year[5] - Total operating revenue for the first three quarters of 2025 reached ¥3,047,039,079.24, a significant increase of 35.8% compared to ¥2,245,006,087.12 in the same period of 2024[24] - Net profit for the first three quarters of 2025 was ¥818,339,617.30, representing a year-over-year growth of 61.3% from ¥507,265,199.52 in 2024[24] - Operating profit increased to ¥868,653,239.12, up 54.3% from ¥562,258,052.99 in the previous year[24] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥1.38, up from ¥0.85 in the same period of 2024[25] Cash Flow and Assets - The company reported a significant increase in net cash flow from operating activities, totaling ¥481.96 million, up 3.57% year-to-date[5] - Cash flow from operating activities generated a net amount of ¥481,960,456.57, compared to ¥465,340,293.85 in the same period last year[27] - Cash and cash equivalents increased to ¥2,064,233,725.12 from ¥902,777,760.68, representing a growth of 128.0%[22] - Cash and cash equivalents at the end of the period totaled ¥338,956,379.99, an increase from ¥272,242,587.07 at the end of the same period in 2024[27] - Total current assets reached ¥4,968,496,815.27, up from ¥3,790,858,209.05, reflecting a growth of 31.1%[22] - Accounts receivable rose to ¥529,627,542.60 from ¥213,714,496.82, an increase of 148.0%[22] - Total assets of the company at the end of the reporting period were ¥12.14 billion, a slight increase of 0.83% from the end of the previous year[5] Liabilities and Equity - Total liabilities decreased to ¥860,365,215.93 from ¥988,445,729.70, a reduction of 12.9%[23] - Total equity attributable to shareholders increased to ¥11,282,392,471.03 from ¥11,054,470,662.18, a rise of 2.1%[23] Sales Performance - Domestic sales revenue for insulin preparations reached ¥2.69 billion, an increase of ¥822 million, with a growth rate of 44.01%[13] - International sales revenue amounted to ¥353 million, up ¥110 million, reflecting a growth of 45.52%[15] Investments and Agreements - The company signed a 10-year supply framework agreement with Brazilian partners, with a total order value expected to exceed ¥3 billion[15] - The company’s long-term investments in non-current financial assets rose to ¥72,190,190.44 from ¥11,713,152.96, an increase of 516.5%[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 94,714[19] - The number of shares held by the largest shareholder, Gan Zhongru, is 205,643,757, representing 34.42% of total shares[19] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[20] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥407,861,819.05, slightly up from ¥403,442,931.89 in 2024, indicating continued investment in innovation[24] Operating Costs - The total operating costs for the first three quarters of 2025 were ¥2,275,937,092.07, an increase of 18.5% from ¥1,921,772,067.24 in 2024[24] Comprehensive Income - The company reported a total comprehensive income of ¥817,932,852.54 for the first three quarters of 2025, compared to ¥506,399,943.50 in 2024[25]